Pacific Biosciences of California, Inc. - Common Stock (NQ:PACB)

1.410 -0.240 (-14.55%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pacific Biosciences of California, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Why PacBio (PACB) Shares Are Getting Obliterated Today

Today 13:00 EDT

What Happened? Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) fell 14.2% in the afternoon session after the company reported mixe...

Via StockStory

Topics Earnings Economy

PacBio (PACB) Q1 2026 Earnings Call Transcript ↗

Today 10:33 EDT

PacBio (PACB) Q1 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

PACB Q1 Deep Dive: Consumables Growth and Clinical Adoption Offset Instrument Weakness

Today 9:30 EDT

Genomics company Pacific Biosciences of California (NASDAQ:PACB) fell short of the market’s revenue expectations in Q1 CY2026, with sales flat year on year a...

Via StockStory

PACIFIC BIOSCIENCES OF CALIF (NASDAQ:PACB) Beats Q4 2025 Revenue and EPS Estimates ↗

February 12, 2026

Via Chartmill

Pacific Biosciences of California Q1 Earnings Call Highlights ↗

Today 8:07 EDT

Pacific Biosciences of California (NASDAQ:PACB) reported first-quarter 2026 revenue of $37.2 million, roughly flat year over year, as record consumables revenue offset weaker-than-expected instrument...

Via MarketBeat

Topics Artificial Intelligence Earnings

3 Small-Cap Stocks We Find Risky

Today 0:31 EDT

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...

Via StockStory

Topics Artificial Intelligence

PacBio (NASDAQ:PACB) Misses Q1 CY2026 Sales Expectations

May 07, 2026

Genomics company Pacific Biosciences of California (NASDAQ:PACB) fell short of the market’s revenue expectations in Q1 CY2026, with sales flat year on year a...

Via StockStory

Topics Artificial Intelligence

PacBio (PACB) Q1 Earnings Report Preview: What To Look For

May 05, 2026

Genomics company Pacific Biosciences of California (NASDAQ:PACB) will be reporting earnings this Thursday after market hours. Here’s what investors should kn...

Via StockStory

1 Cash-Burning Stock with Solid Fundamentals and 2 We Turn Down

April 29, 2026

Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them...

Via StockStory

Bruker, Amneal, Amphastar Pharmaceuticals, Dentsply Sirona, and PacBio Stocks Trade Up, What You Need To Know

April 17, 2026

What Happened? A number of stocks jumped in the afternoon session as the reopening of the Strait of Hormuz signaled a cooling of global logistics and energy ...

Via StockStory

Topics Economy

Ontario-Based DNAstack Leads Sovereign AI for Genomics and Health with Goal of Making Canadians Healthier and Reducing Strain on our Healthcare System

April 07, 2026

Via AB Newswire

Topics Artificial Intelligence Intellectual Property

Azenta, 10x Genomics, PacBio, Oscar Health, and Moderna Shares Plummet, What You Need To Know

March 27, 2026

What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...

Via StockStory

Topics Economy Government Stocks

3 Small-Cap Stocks with Warning Signs

March 19, 2026

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...

Via StockStory

Topics Artificial Intelligence

Life Sciences Tools & Services Stocks Q4 Earnings: Illumina (NASDAQ:ILMN) Firing on All Cylinders

March 17, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Illumina (NASDAQ:ILMN) and it...

Via StockStory

Topics Artificial Intelligence

Fortrea, Alignment Healthcare, PacBio, DexCom, and Humana Stocks Trade Up, What You Need To Know

March 16, 2026

What Happened? A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries. ...

Via StockStory

Topics Economy Stocks

3 of Wall Street’s Favorite Stocks We Think Twice About

March 13, 2026

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...

Via StockStory

Topics Economy

PacBio, CONMED, Moderna, QuidelOrtho, and Tandem Diabetes Shares Are Falling, What You Need To Know

March 06, 2026

What Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the hea...

Via StockStory

Topics Economy

Life Sciences Tools & Services Stocks Q4 Recap: Benchmarking PacBio (NASDAQ:PACB)

March 03, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at PacBio (NASDAQ:PACB) and its ...

Via StockStory

Topics Artificial Intelligence

3 Unprofitable Stocks We Approach with Caution

March 01, 2026

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital...

Via StockStory

PacBio, Myriad Genetics, LeMaitre, Hims & Hers Health, and GoodRx Shares Are Falling, What You Need To Know

February 27, 2026

A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures. The Producer Price Index (PPI), a key...

Via StockStory

Topics Economy Government Stocks

The "Flight to Quality": Thermo Fisher’s Q4 Beat and Dividend Hike Cement Defensive Leadership for 2026

February 27, 2026

WALTHAM, MA — In a market defined by shifting geopolitical alliances and a renewed "flight to quality," Thermo Fisher Scientific (NYSE:TMO) has once again asserted its dominance as the bedrock of the...

Via MarketMinute

Topics Earnings Economy World Trade

Why Is PacBio (PACB) Stock Soaring Today

February 24, 2026

Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 6.3% in the afternoon session after the company announced a collaboration with DNAstack to launch the world's first...

Via StockStory

Topics Government Supply Chain World Trade

Guardant Health, PacBio, Align Technology, QuidelOrtho, and Omnicell Shares Are Falling, What You Need To Know

February 23, 2026

A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court...

Via StockStory

Topics Economy Government World Trade

PacBio (PACB): Buy, Sell, or Hold Post Q4 Earnings?

February 19, 2026

PacBio’s 31.3% return over the past six months has outpaced the S&P 500 by 23.8%, and its stock price has climbed to $1.67 per share. This was partly thanks to its solid quarterly results, and the...

Via StockStory

Topics Bankruptcy Stocks

5 Must-Read Analyst Questions From PacBio’s Q4 Earnings Call

February 19, 2026

Pacific Biosciences’ fourth quarter results exceeded Wall Street’s expectations, supported by record consumables revenue and robust instrument placements, particularly for the Revio and Vega sequencing...

Via StockStory

Topics Earnings

1 Safe-and-Steady Stock with Impressive Fundamentals and 2 We Avoid

February 15, 2026

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

Via StockStory

PACB Q4 Deep Dive: Consumables and Clinical Adoption Drive Growth as SparkNex Launch Nears

February 13, 2026

Genomics company Pacific Biosciences of California (NASDAQ:PACB) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 13.8% year on year to $44.65 million. Its non-GAAP...

Via StockStory

PacBio (PACB) Q4 2025 Earnings Call Transcript ↗

February 12, 2026

PacBio (PACB) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

PacBio (NASDAQ:PACB) Reports Strong Q4 CY2025

February 12, 2026

Via StockStory

PacBio Earnings: What To Look For From PACB

February 10, 2026

Genomics company Pacific Biosciences of California (NASDAQ:PACB) will be announcing earnings results this Thursday after market hours. Here’s what to expect.

Via StockStory

Topics Artificial Intelligence World Trade

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.